{"id":"livalo-ezetrol","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pitavastatin works as a statin by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing LDL cholesterol levels. Ezetimibe selectively blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, preventing dietary and biliary cholesterol absorption. Together, these agents provide complementary mechanisms to reduce circulating cholesterol levels.","oneSentence":"Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:33.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary prevention of cardiovascular disease"},{"name":"Secondary prevention in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06314919","phase":"","title":"A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-03-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":8606},{"nctId":"NCT00653913","phase":"PHASE1","title":"Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT04584736","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-06-11","conditions":"Primary Hypercholesterolemia","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pitavastatin, Ezetimibe"],"phase":"phase_3","status":"active","brandName":"Livalo, Ezetrol","genericName":"Livalo, Ezetrol","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}